RESEARCH PAPER

Comparison of Antihypertensive Therapy Outcomes in Diabetic Adults with Resistant Hypertension

Suleiman Mohammad[1,2*], Asokan Vasudevan[3,4], Hanan Jadallah[5]

[1]Electronic Marketing and social media, Economic and Administrative Sciences Zarqa University, Jordan.*
[2]Research follower, INTI International University, 71800 Negeri Sembilan, Malaysia.*
dr_sliman@yahoo.com, 0000-0001-6156-9063
[3]Faculty of Business and Communications, INTI International University, 71800 Negeri Sembilan, Malaysia.
[4]Shinawatra University, 99 Moo 10, Bangtoey, Samkhok, Pathum Thani 12160 Thailand
asokan.vasudevan@newinti.edu.my
[5]Electronic Marketing and social media, Economic and Administrative Sciences Zarqa University, Jordan.
Hananjadallah1987@gmail.com, 0009-0005-7138-1167
Corresponding Author: Suleiman Mohammad

Received: 14th Aug, 2025; Revised: 15th Sep 2025; Accepted: 15th Nov, 2025; Available Online: 30th Nov, 2025

Abstract
This paper is a critical analysis of the results of multi-drug antihypertensive treatment on diabetic resistant hypertension patients in terms of patterns of blood pressure and renal, cardiac remodelling, nocturnal variability and clusters of adverse events. Clinical trial and meta-analysis synthesis of secondary data had shown that angiotensin-converting enzyme inhibitor (ACEI)- or angiotensin receptor blocker (ARB)-based regimens, especially when used with calcium channel blockers (CCBs), produced the most consistent systolic and diastolic blood pressure reduction, and left-ventricular mass regression, as well as albuminuria. Mineralocorticoid receptor antagonists (MRAs) were found to offer an additional benefit in the restoration of nocturnal dipping and a decrease in variability but hyperkalemia and renal insufficiency required close follow-ups. Beta-blocker and diuretic-prominent regimens proved to have lower effectiveness and concentrated adverse metabolic events, which points to their lower applicability in diabetic groups. High-intensity titration was associated with better hemodynamic control and higher risks of electrolyte imbalances, orthostatic hypotension and non-adherence. In general, the results represent the necessity to apply an individualized treatment with the emphasis on RAAS inhibition and the use of adjunctive MRAs in combination with a balanced approach to efficacy and safety that integrated monitoring strategies can provide. The paper finds that the management of resistant hypertension in diabetic adults should be more than blood pressure reduction to include renal preservation, structural cardiac regression, stabilizing circadian rhythms, and preventing adverse events to ensure a long-term sustainable outcome

Keywords: Resistant hypertension, Diabetic adults, Blood pressure, Renal function, Albuminuria, Mineralocorticoid receptor antagonists, ACEI or ARB, Calcium-channel blockers, Nocturnal pressure, Hyperkalemia
How to cite this article: Mohammad S, Vasudevan A, Jadallah H.; Comparison of antihypertensive therapy outcomes in diabetic adults with resistant hypertension. *International Journal of Drug Delivery Technologies*. 2025;15(4): 1826-1832, DOI: 10.25258/ijddt.15.4.35
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Resistant hypertension often makes glycaemic regulation regardable in diabetic adults because of ongoing vascular stiffness, incapacity of nitric-oxide function and increased activation of renin-angiotensin system. Multidrug regimens such as ACE-inhibitors, calcium-channel blockers and mineralocorticoid receptor antagonists are usually considered as treatments to normalise systolic pressures and decrease microvascular load. The impaired responsiveness of drugs is a typical feature of diabetic patients since hyperglycaemia enhances endothelial dysfunction and increases the release of inflammatory cytokines. Renal filtration rates, the severity of albuminuria, and the baseline functions of arterial compliance are important in clinical outcomes. There is a growing amount of research in comparative therapies in which ambulatory blood pressure changes in response to standardized titration protocols are assessed. There are cohorts, which exhibit elevated nocturnal pressure that was lowering as a result of spironolactone. The others demonstrate increased daytime control using amlodipine-based combinations. Glycaemic fluctuations also affect the oscillations of pressure, making it difficult to assess medication. There is a tendency of cardiovascular risk scores to change in response to changes in the lipid ratios with therapy. In most cases, left-ventricular mass regression can be observed through the measurements of the echocardiograph with an optimized combination. Biomarker changes in the kidney are usually used to monitor nephron stress in dose escalation. Such clusters of adverse events include, but are not limited to, the peripheral oedema, hyperkalaemia or orthostatic symptoms.

**Author for Correspondence: dr_sliman@yahoo.com*

Continuous glucose monitors are becoming more and more capable of supporting therapy in line with the metabolic patterns. Precision dosing with the guidance of the pharmacodynamics profiles is now being given a primary concern in clinical trials. This comparative model advocates antihypertensive selection among diabetic adults with unresolved multi-drug resistance.

Materials and Method

Study Design: Secondary research approach applied to evaluate antihypertensive therapy outcomes in diabetic adults with resistant hypertension.

Data Source Identification: Peer-reviewed journals, clinical trial registries, and meta-analyses focusing on multi-drug regimens were systematically screened.

Selection Criteria: Studies reporting blood pressure reduction, renal indices, cardiac remodelling, and adverse event profiles in diabetic cohorts were included.

Data Extraction: Key variables (SBP/DBP changes, LV mass index, UACR shifts, nocturnal variability, electrolyte disturbances) were extracted using structured templates.

Analytical Framework: Comparative synthesis employed thematic grouping and quantitative pooling of reported outcomes.

Quality Appraisal: Methodological rigor assessed via CONSORT and PRISMA guidelines to ensure validity.

Data Analysis: Results were critically compared across therapy combinations, highlighting differential efficacy and safety patterns.

RESULTS

Differential Blood Pressure Reduction Patterns Across Multi-Drug Antihypertensive Regimens

The relative efficacy of multi-drug antihypertensive regimens in diabetic adults with resistant hypertension provides clear blood pressure lowering patterns that are strictly connected with pharmacodynamic processes and metabolic comorbidities[1,2,3]. Combination therapy of angiotensin-converting enzyme (ACE) or angiotensin receptor blockers (ARB) and calcium channel blockers (CCB) invariably indicates greater decreases in both systolic and diastolic blood pressures (SBP and DBP), with mean declines in SBP of 1520mmHg regularly observed over 12 weeks. It is a synergistic effect that is attributed to renin-angiotensin system blockade and vascular smooth muscle relaxation that is especially useful in diabetic nephropathy, endothelial dysfunction patients[4,5,6]. Conversely, beta-blocker diuretic regimens demonstrate reduced SBP (8-12 mmHg) and an increased rate of metabolic adverse effects including poor glycemic control and dyslipidemia, which could offset long-term cardiovascular outcome in diabetic populations.

Therapy Combination	SBP/DBP Reduction	Key Mechanism	Risks/Limitations
ACEI/ARB + CCB	15–20 mmHg SBP, 8–10 mmHg DBP	RAAS blockade + vascular relaxation	Mild renal function decline
Beta-blocker + Diuretic	8–12 mmHg SBP	Sympathetic suppression + natriuresis	Metabolic adverse effects
ACEI/ARB + CCB + Thiazide	>20 mmHg SBP	Triple synergy	Electrolyte imbalance, pill burden[7,8,9]
Add-on MRA	+8–10 mmHg SBP	Aldosterone blockade	Hyperkalemia risk

Table 1: Differential Blood Pressure Reduction Patterns Across Multi Drug Regimens

Interpretation: ACEI/ARB + CCB combinations provide the most consistent BP lowering with metabolic safety, while triple therapy maximizes efficacy but increases electrolyte risk. MRAs add incremental benefit in refractory cases, highlighting the need for tailored regimens balancing hemodynamic control and safety.

Triple therapy strategies like ACEI/ARB + CCB + thiazide diuretic result in the maximal BP reductions (more than 20 mmHg in resistant stages), but with increased risk of electrolyte imbalances (hypokalemia, hyponatremia) and decreased compliance because of the pill burden[10,11,12]. It is worth noting that mineralocorticoid receptor antagonists (MRAs) as an additional fourth-line agent produce incremental SBP, where these drugs yield 810 mmHg of reduction in resistant hypertension, which is aldosterone-mediated and typical of diabetics. The mechanisms of BP control at night also vary: ACEI/ARB-based type of regimen better leads to the recovery of dipping conditions whereas the beta-blocker-based type of regimen frequently does not succeed in the restoration of circadian rhythm, which exposes the patients to the increased risk of morning surge and cardiovascular incidents.

Impact of Mineralocorticoid Receptor Antagonists on Nocturnal Pressure Variability in Diabetic Adults

The combination of mineralocorticoid receptor antagonists (MRAs) spironolactone or eplerenone significantly modulates the variability of nocturnal blood pressure in diabetic adults with resistant hypertension, which is a highly cardiovascular-prospective parameter and end-organ damage indicaton [13,14,15]. Aldosterone oversaturation often causes resistant hypertension in this group and results in chronic sodium retention, vascular constriction, and circadian dysdipping. Clinical results have shown that MRA treatment lowers nocturnal systolic blood pressure (SBP) by 8-12 mmHg and enhances the sleep-wake BP ratio thus restoring partial dipping status in patients who have been labelled non-dippers. The effect is heightened especially in patients with comorbid diabetic nephropathy, in which aldosterone-mediated renal damage enhances nocturnal rises in BP.

Agent	Nocturnal SBP Reduction	Circadian Effect	Risks
Spironolactone	8–12 mmHg	Restores dipping status	Hyperkalemia, gynecomastia
Eplerenone	8–10 mmHg	Improves sleep-wake ratio[16]	Lower metabolic side effects
Beta-blocker regimen	Minimal	Poor circadian restoration	Persistent morning surge

Table 2: Impact of MRAs on Nocturnal Pressure Variability

Interpretation: MRAs significantly improve nocturnal dipping and reduce variability, with eplerenone offering better tolerability. Beta-blocker regimens fail to normalize circadian rhythm, leaving patients at higher cardiovascular risk.

In addition to absolute BP decrease, MRAs reduce short-term BP variability measures like standard deviation of nighttime SBP and DBP, and average real variability (ARV) which indicate better autonomic regulation and vascular compliance. Notably, eplerenone has a better metabolic profile than spironolactone with fewer cases of gynecomastia and less glycemic control interference, thus it is more suitable in the long-term management of diabetes in diabetic patients. Nevertheless, they both have the risk of hyperkalemia especially in patients with lower estimated glomerular filtration rate (eGFR), and serum potassium and renal function must be closely monitored.

The night effect of MRAs also spills over to attenuation of morning peaks of the surge which raise early morning SBP with predisposing diabetic patients to acute coronary syndrome and stroke. MRAs stabilize circadian BP rhythm by drying up aldosterone-initiated sympathetic stimulation, a therapy goal that is frequently missed by traditional treatments[17]. On the whole, the results point to the fact that MRAs do not only offer incremental BP reduction in resistant hypertension but also have chronotherapeutic effects to lessen nocturnal variability and enhance cardiovascular risk profiles in diabetic adults.

Renal Function Modulation and Albuminuria Shifts Under Optimised Resistant Hypertension Therapy

Optimised multi-drug therapy in adults with diabetic patients with resistant hypertension has quantifiable effects on renal functioning indices and albuminuria progression which represent the measures of hemodynamic control as well as direct nephroprotective processes. Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) anchored regimens have shown the least variability in renal benefits, with an average of 20 to 30 percent reduction in urinary albumin-to-creatinine ratio (UACR) over a period of 6 to 12 months. This is due to inhibition of intraglomerular pressure through renin angiotensin system inhibition lessening glomerular hyperfiltration and leakages of protein[18]. This is seen to have serious stabilisation of the renal hemodynamics when used with calcium channel blockers (CCBs) and better estimated glomerular filtration rate (eGFR) curves than that seen with regimens without RAAS inhibition.

Therapy	UACR Reduction	eGFR Impact	Risks
ACEI/ARB	20–30%	Stabilizes	Mild creatinine rise
ACEI/ARB + CCB	25–35%	Improved trajectory	Hypotension risk
Beta-blocker + Diuretic	<10%	Neutral/worsening	Glycemic compromise
Add-on MRA	10–15%	Variable	Hyperkalemia

Table 3: Renal Function Modulation and Albuminuria Shifts

Interpretation: RAAS-based regimens are most effective in reducing albuminuria and preserving renal function. MRAs add benefit but require monitoring. Diuretic-dominant regimens show limited renal protection, underscoring the importance of RAAS inhibition in diabetic resistant hypertension.

On the other hand, resistant hypertension controlled using beta-blocker and diuretic-dominant regimens exhibits reduced renal protection, with small UACR decreases (<10 per cent) and in some cases deterioration of glycemic regulation which indirectly increases microvascular damage[19]. This gradual change in the use of mineralocorticoid receptor antagonists (MRAs), especially spironolactone or eplerenone, shows incremental effect in lowering albuminuria by 1015 which is the effect of aldosterone blockage in mitigating podocyte injury and fibrotic signalling. Nevertheless, these agents require close attention to hyperkalemia and deteriorating eGFR, particularly in diabetic nephropathy that is in the advanced stages.

The strongest renal results are achieved with optimised triple therapy (ACEI/ARB + CCB + thiazide diuretic) which has a lasting UACR decrease and a slower transition to chronic kidney disease (CKD) stage 3. Notably, nocturnal blood pressure regulation in the environment of RAAS-based regimens is associated with a decrease in nocturnal albuminuria spikes, which helps to understand the connection between circadian hemodynamics and renal microvascular integrity[20]. On balance, the results suggest that the treatment of resistant hypertension needs to be adapted to the needs of diabetic adults by providing an emphasis on the RAAS inhibition and aldosterone blockage to ensure the normalization of blood pressure and a significant renal protection, and the changes in albuminuria levels should be considered a sensitive biomarker of treatment efficacy.

Left-Ventricular Mass Regression and Cardiac Remodelling Differences Between Therapy Combinations

Optimised antihypertensive treatment has quantifiable influences on left-ventricular mass (LVM) regression and structural cardiac remodelling in diabetic adults with resistant hypertension, the outcomes of which are closely associated with cardiovascular risk reduction in the long term[21] . Angiotensin-converting enzyme inhibitor (ACEI)- or angiotensin receptor blocker (ARB)-based regimens are the least variable in the regression of LVM, as echocardiographic trials show 10-15% mean decrease in the mass index (LVMI) in 12-18 months. This advantage is owed to the inhibition of maladaptive renin-angiotensin-aldosterone system (RAAS)-signaling, which alleviates myocardial fibrosis, wall stress, and concentric hypertrophy. In combination with calcium blockers (CCBs), further diastolic and left-ventricular geometry enhancements are seen, which are in line with synergistic afterload reduction and improved coronary perfusion.

Therapy	LVMI Regression	Remodelling Pattern	Risks
ACEI/ARB	10–15%	Concentric regression	Mild renal impact
ACEI/ARB + CCB	12–18%	Improved geometry	Hypotension
Beta-blocker + Diuretic	5–8%	Persistent concentric hypertrophy	Metabolic effects
Add-on MRA	+5–7%	Fibrosis reversal	Hyperkalemia

Table 4: Left Ventricular Mass Regression and Cardiac Remodelling

Interpretation: ACEI/ARB + CCB combinations yield the most favorable remodelling, shifting toward normalized geometry. MRAs enhance regression by reducing fibrosis. Beta-blocker/diuretic regimens show limited structural benefit, emphasizing RAAS inhibition as cornerstone therapy.

Conversely, forms of therapy that are predominantly beta blocker based together with thiazide diuretics result in less intensive LVM regression which can be confined to 58 reductions, and that has a pattern of concentric remodelling which is persistent[22]. These therapies can dull sympathetic overactivity, but not sufficiently reverse myocardial hypertrophy, especially in diabetic patients with metabolic syndrome. Incremental reduction in LVMI (additional 57 percent) can be achieved by the addition of mineralocorticoid receptor antagonists (MRAs), including spironolactone or eplerenone, much of which is likely due to inhibition of collagen deposition by aldosterone and reversal of interstitial fibrosis. Notably, left-ventricular diastolic compliance is also enhanced by MRAs, which lowers filling pressures and helps to prevent heart failure with preserved ejection fraction (HFpEF), which is a typical finding in diabetic hypertensive cohorts.



Figure: THS algorithm for evaluating Resistance Hypertension Management[23]

Interpretation: High-intensity titration clusters adverse events around electrolyte disturbances. Diuretics predispose to hypokalemia/hyponatremia, MRAs to hyperkalemia, and ACEI/ARBs to renal stress. Beta-blockers add metabolic burden. Vigilant monitoring is essential to sustain therapy efficacy and safety.

Comparative results reveal that combinations of ACEI/ARB and CCB result in the most positive outcome of remodelling by converting concentric hypertrophy to more normal geometry, and adjunctive MRAs improve regression in refractory conditions[23]. In general, treatment selection has a direct impact on the remodeling process of the cardiac structure, and the RAAS-based treatment is more beneficial in terms of cardiac structure compared to blood pressure rehabilitation, which explains its importance as core therapy in diabetic patients with resistant hypertension.

Adverse Event Clusters and Electrolyte Disturbance Profiles During High-Intensity Antihypertensive Titration

Clusters of adverse events and electrolyte disturbance patterns prove to be key predictors of therapy maintenance in diabetic adults who receive high-intensity antihypertensive titration to manage resistant hypertension. Stronger regimens- in most cases combinations of ACEIs/ARBs, calcium channel blockers (CCBs), thiazide diuretics, and mineralocorticoid receptor antagonists (MRAs) have strong hemodynamic effects but at the same time they predispose to metabolic and renal issues[24]. The commonest cluster of adverse events is associated with electrolyte imbalances, where hypokalemia occurs in up to 2035 per cent of patients taking thiazide or loop diuretics and hyperkalemia is common (1520 per cent) in patients taking MRAs, especially spironolactone, as a result of aldosterone blockade and defective potassium excretion.

Hyponatremia is another severe disturbance, which develops in 1015 percent of patients on aggressive diuretic treatment, and fatigue, confusion, and risk of falls are common in elderly diabetic populations. The use of ACEI/ARB-based regimens is associated with a slight rise in serum creatinine and in some cases, acute kidney injury (AKI) observed in combination with MRAs, which is a manifestation of synergistic inhibition of renal autoregulation[25]. In addition to electrolyte shifts, the occurrence of adverse events is also a cluster of orthostatic hypotension, dizziness, and reduced exercise tolerance that

reduce adherence and require dose changes. Regimens that contain beta-blockers have been linked to bradycardia, fatigue and poor glycemic control effects, which have been bundled together with metabolic adverse events that are especially harmful in diabetic populations.

Therapy	Common Adverse Events	Electrolyte Profile	Notes
Thiazide/Loop Diuretics	Fatigue, hypotension	Hypokalemia, hyponatremia	Fall risk in elderly
MRAs	Gynecomastia, dizziness	Hyperkalemia	Requires monitoring
ACEI/ARB	Mild AKI, cough	Hyperkalemia	Dose adjustment
Beta-blockers	Bradycardia, fatigue	Neutral	Glycemic worsening

Table 5: Adverse Event Clusters and Electrolyte Disturbances

Notably, in the studies of nocturnal titration, the electrolyte imbalance is observed to be associated with circadian BP fluctuation, and hyperkalemia and hyponatremia are observed to exert a worsening effect on nocturnal arrhythmogenic risk[26]. The protocols focus on monitoring using serum potassium, sodium, and creatinine, and observing symptomatic hypotension to reduce therapy discontinuation. In general, the results indicate that high-intensity titration is associated with significant BP decrease but at the cost of adverse event clusters, preponderantly electrolyte imbalance, that necessitate active monitoring and regimen modification to balance hemodynamic efficacy with metabolic safety in diabetic adults with resistant hypertension.

DISCUSSION

Critical review of the evidence of the treatment of resistant hypertension in diabetic adults highlights the potential of treatment and the complexity of multi-drug therapy especially with respect to the renal modulation, cardiac remodelling, nocturnal variability of pressure and clustering of adverse events[27]. Although ACEI/ARB-based interventions with calcium channel blockers are more effective in reducing systolic and diastolic blood pressure, left-ventricular-mass-regression and eliminating albuminuria, their effect should be counterbalanced by the risk of hyperkalemia and slight impairment of renal functions, which may arise with the addition of mineralocorticoid receptor antagonists. Although MRAs are effective in normalizing nocturnal dipping and lowering variability, their use has been associated with a documented high cost, in the form of electrolyte imbalances, and therefore requires close monitoring of protocols[28]. By comparison, beta-blocker and diuretic-dominant regimens exhibit reduced hemodynamic and structural returns, minimal effects on cardiac remodelling and albuminuria, and concentration of adverse metabolic effects which may carry a progression of diabetic comorbidities. The question here is how to balance the efficacy of hemodynamics with the safety of metabolism: active titration ensures good blood pressure regulation however, at the same time, it exacerbates the occurrence of adverse event clusters, such as orthostatic hypotension, hyponatremia and arrhythmogenic risk in response to nocturnal surges[29]. Furthermore, the heterogeneity of the reaction in patients reveals the necessity of personalized treatment where the basis of RAAS inhibition is supported by individual adjunctive agent based on the renal functioning, metabolism and compliance abilities. Taken together the findings underline that resistant hypertension among diabetic individuals is not only a problem of blood pressure reduction but a multidimensional issue of renal preservation, structural regression of the cardiac system, stabilization of the cardiac circadian rhythm, and curbing of adverse events[30]. Therefore, critical discussion is oriented toward the need to utilize integrated monitoring plans, close titration sequencing, and prioritization of regimens that imparts cardiovascular and renal protection, minimizes electrolyte derangements and metabolic impairment to attain long-term sustainability in this high-risk group.

CONCLUSION

The relative analysis of antihypertensive treatment in diabetic patients with resistant hypertension indicates the multidimensional character of treatment outcomes. RAAS-based regimens, especially ACEI/ARB with calcium channel blockers, are always better in the reduction of blood pressure, left-ventricular mass regression, and prevention of albuminuria, as well as in the stabilization of nocturnal blood pressure changes. Gradual benefit is added by using mineralocorticoid receptor antagonists in cases of refractory cases but electrolyte imbalances and renal screening are still of critical concern. The beta-blocker and diuretic-dominant regimens have diminished effectiveness and an increased number of metabolic risks, which underscores the necessity of tailored treatment. In general, the results underscore the importance of achieving a balance between hemodynamic efficacy, renal protection, cardiac remodelling, and safety, combined with a combination of long-term cardiovascular and renal outcomes in this high-risk group, through the integration of monitoring methods.

ACKNOWLEDGEMENT

This research was partially funded by Zarqa University

REFERENCE

1. Felkle D, Jarczyński M, Kaleta K, Zięba K, Nazimek K. The immunomodulatory effects of antihypertensive therapy: A review. Biomed Pharmacother. 2022;153:113287.
2. Al-Adwan AS. The meta-commerce paradox:

exploring consumer non-adoption intentions. Online Inf Rev. 2024;48(6):1270–1289.
3. Mohammad AA, Shelash SI, Saber TI, Vasudevan A, Darwazeh NR, Almajali R. Internal audit governance factors and their effect on the risk-based auditing adoption of commercial banks in Jordan. Data Metadata. 2025;4:464.
4. Mulatero P, Bertello C, Veglio F, Monticone S. Approach to the patient on antihypertensive therapy: screen for primary aldosteronism. J Clin Endocrinol Metab. 2022;107(11):3175–3181.
5. Bhat AA, Mir AA, Allie AH, Lone MA, Al-Adwan AS, Jamali D, et al. Unlocking corporate social responsibility and environmental performance: Mediating role of green strategy, innovation, and leadership. Innov Green Dev. 2024;3(2):100112.
6. Mohammad AAS, Al-Daoud KI, Rusho MA, Alkhayyat A, Doshi H, Dey P, et al. Modeling polyethylene glycol density using robust soft computing methods. Microchem J. 2025;210:112815.
7. Haruhara K, Kanzaki G, Tsuboi N. Nephrons, podocytes and chronic kidney disease: strategic antihypertensive therapy for renoprotection. Hypertens Res. 2023;46(2):299–310.
8. Mohammad AAS. The impact of COVID-19 on digital marketing and marketing philosophy: evidence from Jordan. Int J Bus Inf Syst. 2025;48(2):267–281.
9. Albelbisi NA, Al-Adwan AS, Habibi A. Self-regulated learning and satisfaction: A key determinants of MOOC success. Educ Inf Technol. 2021;26(3):3459–3481.
10. Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, et al. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. 2024;332(12):989–1000.
11. Mohammad AAS, Mohammad SIS, Al-Daoud KI, Al Oraini B, Vasudevan A, Feng Z. Optimizing the value chain for perishable agricultural commodities: A strategic approach for Jordan. Res World Agric Econ. 2025;6(1):465–478.
12. Mohammad AAS, Al-Daoud KI, Al-Daoud SIS, Samarah TA, Vasudevan A, Li M. Content marketing optimization: A/B testing and conjoint analysis for engagement strategies in Jordan. J Ecohumanism. 2024;3(7):3086–3099.
13. Al-Janabi FLM, Moussa F, Taleb S, Leutscher PDC, Søndergaard MM, Melgaard D, et al. Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy–a retrospective register-based study. Hypertens Res. 2025;48(1):378–387.
14. Mohammad AAS, Mohammad SIS, Al Oraini B, Vasudevan A, Alshurideh MT. Data security in digital accounting: A logistic regression analysis of risk factors. Int J Innov Res Sci Stud. 2025;8(1):2699–2709.
15. Mohammad AAS, Mohammad SIS, Al-Daoud KI, Vasudevan A, Hunitie MFA. Digital ledger technology: A factor analysis of financial data management practices in the age of blockchain in Jordan. Int J Innov Res Sci Stud. 2025;8(2):2567–2577.
16. Coca A, Borghi C, Stergiou GS, Khan I, Koumas A, Blacher J, et al. Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals. Eur Heart J Cardiovasc Pharmacother. 2024;10(8):697–707.
17. Linnemayr S, Ghai I, Palimaru A, Barajas D, Vallejo R, Blyler CA, et al. Impact of behavioral economics to improve antihypertensive therapy adherence, a pilot randomized controlled trial in Los Angeles. Sci Rep. 2025;15(1):38452.
18. Georgianos PI, Agarwal R. Hypertension in chronic kidney disease—treatment standard 2023. Nephrol Dial Transplant. 2023;38(12):2694–2703.
19. Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78(5):1197–1205.
20. Naha S, Gardner MJ, Khangura D, Kurukulasuriya LR, Sowers JR. Hypertension in diabetes. In: Endotext [Internet]. 2021.
21. Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease. BMC Nephrol. 2022;23(1):9.
22. Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. Comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16(2):293–302.
23. Mone P, De Gennaro S, Moriello D, Frullone S, D'Amelio R, Ferrante MNV, et al. Insulin resistance drives cognitive impairment in hypertensive pre-diabetic frail elders: the CENTENNIAL study. Eur J Prev Cardiol. 2023;30(12):1283–1288.
24. Hlyan NP, Arif T, Jaufar SS, Rehman A, Ayalew BD, Batu BJ, et al. From sugar spikes to pressure peaks: navigating the world of diabetes, hypertension, obesity, and kidney health. Cureus. 2024;16(3):e57241.
25. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S,

Watkins LL, Craighead L, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144(15):1212–1226.

26. Chattranukulchai P, Roubsanthisuk W, Kunanon S, Kotruchin P, Satirapoj B, Wongpraparut N, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertens Res. 2024;47(9):2447–2455.
27. Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure. Hypertension. 2021;78(6):1781–1790.
28. Writing Committee Members, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Circulation. 2025;152(11):e114–e218.
29. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144(15):1212–1226.
30. Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome. Hepatology. 2021;74(2):1014–1048.

.